De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ABVC BioPharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

ABVC BioPharma heeft een totaal eigen vermogen van $7.8M en een totale schuld van $2.1M, wat de schuld-eigenvermogensverhouding op 27.2% brengt. De totale activa en totale passiva bedragen respectievelijk $14.6M en $6.8M.

Belangrijke informatie

27.2%

Verhouding schuld/eigen vermogen

US$2.13m

Schuld

Rente dekkingsratio	n/a
Contant	US$199.98k
Aandelen	US$7.83m
Totaal verplichtingen	US$6.81m
Totaal activa	US$14.63m

Recente financiële gezondheidsupdates

Recent updates

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

Mar 13

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Oct 05

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

Sep 23

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Aug 18

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

Aug 17

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

Jul 13

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

Jun 30

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $2.2M ) van ABVC } dekken niet de korte termijn passiva ( $6.5M ).

Langlopende schulden: De kortetermijnactiva ABVC ( $2.2M ) overtreffen de langetermijnschulden ( $256.5K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 24.6% ) ABVC wordt als voldoende beschouwd.

Schuld verminderen: ABVC had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ABVC heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: ABVC heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 18.2 % per jaar.

ABVC BioPharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

Recent updates

ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma, Inc. announced delayed 10-Q filing

Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million.

ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022)

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2)

Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder

ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601

ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC BioPharma Receives Non-Compliance Letter from Nasdaq

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma, Inc. Announces Board Changes

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC

Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

ABVC BioPharma, Inc. Announces Board Elections

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million.

ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject

ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process

Insufficient new directors

ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

High number of new directors

Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

High number of new directors

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Second quarter 2021 earnings released: US$0.081 loss per share (vs US$0.095 loss in 2Q 2020)

High number of new directors